海南普利制药股份有限公司 独立董事关于第四届董事会第二十次会议相关事项的独立意见 根据《公司法》、《证券法》、《深圳证券交易所创业板股票上市规则》、《上市 公司独立董事规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等相关法律法规、规范性文件及《公司章程》的有关规定， 我们作为海南普利制药股份有限公司（以下简称"公司"）的独立董事，本着认 真、负责的工作态度，在查阅公司提供的有关资料，充分了解相关情况后，我们 对以下相关事项进行了认真审查，发表独立意见如下: 一、关于控股股东、实际控制人及其他关联方占用公司资金的独立意见 据《上市公司监管指引第 8 号--上市公司资金往来、对外担保的监管要求》 （证监会公告〔2022〕26 号）、《公司章程》的规定，我们对公司截止 2023 年 6 月 30 日的资金占用情况进行核查。 经核查，我们认为，报告期内公司不存在控股股东、实际控制人及其他关联 方非经营性占用公司资金的情况，也不存在以前年度发生并延续至本报告期的关 联方违规占用公司资金情况。 经核查，公司于 2023 年 4 月 23 日召开第四届董事会第十五次会议、第四届 监事会 ...

通过上市许可的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 海南普利制药股份有限公司的全资子公司浙江普利药业有限公司于近日收 到国家药品监督管理局（以下简称"NMPA"）所签发的伏立康唑干混悬剂的上市 许可，现将相关情况公告如下： 一、药品基本情况 （一）药物名称：伏立康唑干混悬剂 （二）适应症：本品为广谱的三唑类抗真菌药，适用于治疗成人和2岁及2 岁以上儿童患者的下列真菌感染：1、侵袭性曲霉病。2、非中性粒细胞减少患者 的念珠菌血症。3、对氟康唑耐药的念珠菌引起的严重侵袭性感染（包括克柔念 珠菌）。4、由足放线病菌属和镰刀菌属引起的严重感染。本品主要用于进展性 的、可能威胁生命的真菌感染性患者的治疗。预防接受异基因造血干细胞移植（ HSCT）的高危患者的侵袭性真菌感染。 | 证券代码:300630 | 证券简称:普利制药 | 公告编号:2023-102 | | --- | --- | --- | | 债券代码:123099 | 债券简称:普利转债 | | 海南普利制药股份有限公司 关于伏立康唑干混悬剂获得国家药品监督管理局（NMPA） 伏立康唑的作用 ...

海南普利制药股份有限公司 第四届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 证券代码:300630 证券简称:普利制药 公告编号:2023-097 债券代码:123099 债券简称:普利转债 经审议，董事会通过了公司《关于公司 2023 年半年度募集资金存放与使用 海南普利制药股份有限公司（以下简称"公司"）第四届董事会第二十次会 议于 2023 年 8 月 13 日以电子邮件和电话的方式发出召开通知，会议于 2023 年 8 月 23 日在公司总部会议室以现场结合电话会议的方式召开。会议应到董事 7 名，实到 7 名，公司监事、高管列席会议，本次会议由公司董事长范敏华女士主 持。本次会议的召开符合《公司法》、《证券法》和《公司章程》等相关规定，本 次会议合法有效。 二、会议审议情况 会议各项议案获得出席董事一致同意，形成以下决议： （一）审议并通过了《关于公司 2023 年半年度报告全文及摘要的议案》 出席会议的董事认真审阅了《2023 年半年度报告全文及摘要》等资料，认 为公司编制的《2023 年半年度报告 ...

| 证券代码：300630 | 证券简称：普利制药 | 公告编号：2023-099 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转债 | | 海南普利制药股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等有关规定，海南普利制药股份有限公司（以下简 称"公司"）董事会编制了 2023 年半年度募集资金存放与使用情况的专项报告， 专项报告具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意海南普利制药股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可〔2021〕106 号），公司由主 承销商海通证券股份有限公司向不特定对象发行可转换公司债券 850 万张，每张 面值为人民币 100 元。本次发行的募集资金总额 ...

| 证券代码：300630 | 证券简称：普利制药 | 公告编号：2023-095 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转债 | | 海南普利制药股份有限公司 （一）药品名称：注射用比伐芦定 （二）适应症：适用于接受经皮冠状动脉介入术（PCI）的成人患者，包括 ST 段抬高型心肌梗死（STEMI）患者的治疗。适用于计划紧急或早期干预的不 稳定型心绞痛/非 ST 段抬高型心肌梗死(UA/NSTEMI)成人患者的治疗。 （三）剂型：注射剂 （四）规格：250 mg （五）生产厂家：海南普利制药股份有限公司 二、药品的其他相关情况 关于注射用比伐芦定获得澳大利亚药物管理局（TGA） 上市许可的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 海南普利制药股份有限公司（以下简称"普利制药"或"公司"）于近日收到了 澳大利亚药物管理局（TGA）签发的注射用比伐芦定的上市许可，现将相关情况 公告如下： 一、药品基本情况 2020 年 6 月获得了德国联邦药物和医疗器械管理局（BfArM）的批准；于 2020 年 9 ...

证券代码： 300630 证券简称：普利制药 海南普利制药股份有限公司 投资者关系活动记录表 编号：2023-004 4、汇率变化对公司利润有影响吗？ 尊敬的投资者，您好。汇率的波动对公司暂时未产生重大影 响，谢谢。 5、请问公司 β-烟酰胺单核苷酸产品的应用领域？ 尊敬的投资者，您好。β-烟酰胺单核苷酸产品主要应用于 抗衰保健食品和医学药物，例如 DNA 修复、解酒护肝、抗衰老、 保护视力、防治糖尿病等。目前公司 β-烟酰胺单核苷酸产品已 经完成了酶催化技术路线的开发，以葡萄糖为底物的全发酵路线 正在开发中，谢谢。 6、请问公司今年国内市场主要驱动力在哪？ 投资者关系活动 类别 □特定对象调研 □ 分析师会议 □ 媒体采访 √业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 参与单位名称及 人员姓名 投资者网上提问 时间 2023 年 5 月 26 日 (周五) 下午 14:30~17:00 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） 采用网络远程的方式召开业绩说明会 上市公司接待人 员姓名 1、董事会秘书周茂 2、财务总监罗佟凝 3、证券事务代表吴世 ...

| 证券代码：300630 | 证券简称：普利制药 | 公告编号：2023-062 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转债 | | 海南普利制药股份有限公司 关于参加"2022 年度海南辖区上市公司业绩说明会"的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让投资者 更准确地读懂年度报告、更全面地了解上市公司，切实提高上市公司透明度和治 理水平，海南普利制药股份有限公司（以下简称"公司"）将参加由海南证监局 与深圳市全景网络有限公司、海南上市公司协会联合举办"海南辖区投资者网上 集体接待日暨上市公司业绩说明会"活动，活动时间为 2023 年 5 月 26 日 14:30-17:00，平台登陆地址为：http://rs.p5w.net。 届时，公司主要高管人员将参加本次活动，通过网络在线交流形式，就公司 2022 年年报披露、财务数据、公司治理、内部控制、发展战略、经营状况、现 金分红、重大事项、可持续发展等投资者所关心的问题，与投资者进行" ...

Financial Performance - The company's revenue for Q1 2023 was CNY 373,166,292.20, representing a 1.42% increase compared to CNY 367,925,505.63 in the same period last year[13] - Net profit attributable to shareholders decreased by 14.43% to CNY 138,433,086.41 from CNY 161,777,968.14 year-on-year[13] - The total comprehensive income for the first quarter of 2023 was approximately CNY 138.43 million, a decrease from CNY 161.78 million in the same period last year, representing a decline of about 14.4%[43] - Basic and diluted earnings per share for the first quarter were CNY 0.32, down from CNY 0.37 in the previous year, indicating a decrease of approximately 13.5%[43] Cash Flow - The net cash flow from operating activities increased by 29.21% to CNY 28,782,865.71 compared to CNY 22,275,788.10 in the previous year[13] - Cash inflow from operating activities totaled CNY 446.38 million, an increase of 24.8% compared to CNY 357.66 million in the same period last year[43] - Cash outflow from operating activities was CNY 417.60 million, up from CNY 335.38 million, resulting in a net cash flow from operating activities of CNY 28.78 million, an increase of 29.5% year-over-year[43] - The company's cash flow statement indicates a stable cash position, with no significant changes reported in cash flow from operating activities[26] - The ending balance of cash and cash equivalents was CNY 530.38 million, compared to CNY 470.60 million at the end of the previous year, reflecting a decrease in cash reserves[45] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 6,199,028,028.60, a 25.50% increase from CNY 4,939,389,761.87 at the end of the previous year[13] - The company's cash and cash equivalents decreased to CNY 558,387,952.23 from CNY 777,248,693.86[19] - Accounts receivable increased to CNY 1,014,589,461.88 from CNY 924,070,859.41, indicating a growth of approximately 9.7%[19] - Current liabilities decreased to CNY 1,248,308,071.79 from CNY 1,484,098,044.10, a reduction of approximately 15.9%[22] - Long-term borrowings increased to CNY 999,238,137.82 from CNY 689,214,991.96, representing a growth of about 45%[22] - The total liabilities rose to ¥3,258,533,476.71 from ¥3,156,510,196.83, an increase of approximately 3.23%[36] Investment and Expenses - The company reported a significant increase in investment income, rising by 1646.10% to CNY 2,463,766.47 from CNY 141,101.23 in the previous year[16] - Research and development expenses amounted to ¥61,517,923.07, compared to ¥56,659,055.19 in the previous period, indicating an increase of about 8.25%[24] - Total operating costs increased to ¥243,515,781.30 from ¥212,061,775.12, marking a rise of about 14.85%[24] - Tax expenses decreased to ¥1,076,155.70 from ¥6,010,278.61, a reduction of approximately 82.06%[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,586[16] - The company has a total of 113,674,906 shares, with 25% of these shares subject to a lock-up period[18] - The total equity attributable to shareholders increased to ¥2,940,494,551.89 from ¥2,802,510,631.14, reflecting a growth of about 4.93%[36]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 373,166,292.20, an increase of 1.42% compared to CNY 367,925,505.63 in the same period last year[5] - Net profit attributable to shareholders decreased by 14.43% to CNY 138,433,086.41 from CNY 161,777,968.14 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 128,887,445.84, down 13.28% from CNY 148,627,173.03 in the previous year[5] - Total operating revenue for the current period reached ¥373,166,292.20, an increase from ¥367,925,505.63 in the previous period, representing a growth of approximately 0.66%[32] - Net profit for the current period was ¥138,433,086.41, down from ¥161,777,968.14, indicating a decrease of approximately 14.39%[34] - The total comprehensive income attributable to the parent company's owners was approximately $138.43 million, down from $161.78 million in the previous period, representing a decrease of about 14.4%[49] - Basic and diluted earnings per share were both $0.32, compared to $0.37 in the previous period, reflecting a decline of approximately 13.5%[49] Cash Flow - The net cash flow from operating activities increased by 29.21% to CNY 28,782,865.71 compared to CNY 22,275,788.10 in the same period last year[5] - Cash inflow from operating activities totaled approximately $446.38 million, an increase of about 25% from $357.66 million in the previous period[49] - Cash outflow from operating activities was approximately $417.60 million, up from $335.38 million, indicating an increase of about 24.5%[49] - The net cash flow from operating activities was approximately $28.78 million, an increase of about 29.5% compared to $22.28 million in the previous period[49] - Cash outflow from investing activities was approximately $380.89 million, compared to $319.84 million in the previous period, representing an increase of about 19.1%[52] - The net cash flow from investing activities was negative at approximately $380.89 million, worsening from a negative $215.46 million in the previous period[52] - Cash inflow from financing activities was approximately $416.41 million, down from $448.28 million, indicating a decrease of about 7.1%[52] - The net cash flow from financing activities was approximately $137.24 million, a decrease of about 38.9% from $224.92 million in the previous period[52] - The ending cash and cash equivalents balance was approximately $530.38 million, compared to $470.60 million in the previous period, reflecting an increase of about 12.7%[52] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,199,028,028.60, reflecting a growth of 4.03% from CNY 5,959,020,827.97 at the end of the previous year[5] - Total current liabilities were CNY 1,248,308,071.79, compared to CNY 1,484,098,044.10 previously[30] - The total liabilities increased to ¥3,258,533,476.71 from ¥3,156,510,196.83, showing a growth of approximately 3.23%[45] - Long-term borrowings increased to CNY 999,238,137.82 from CNY 689,214,991.96[30] - The company's short-term borrowings decreased to CNY 484,841,770.00 from CNY 613,389,696.81[30] Equity and Shareholder Information - Shareholders' equity attributable to the parent company increased by 4.92% to CNY 2,940,494,551.89 from CNY 2,802,510,631.14 at the end of the previous year[5] - The total equity attributable to shareholders of the parent company increased to ¥2,940,494,551.89 from ¥2,802,510,631.14, representing a growth of about 4.93%[45] - The company has a total of 31,026,544 shares held by its largest shareholder, Zhu Xiaoping[24] Expenses and Income - The company's inventory increased by 50.53% to CNY 485,459,996.95, up from CNY 322,510,850.58, indicating an increase in production stock[23] - The company's financial expenses decreased by 51.06% to CNY 8,759,306.14 from CNY 17,898,376.80, due to the capitalization of interest expenses[23] - The company received government subsidies amounting to CNY 9,070,325.65, a decrease of 30.31% compared to CNY 13,015,588.30 in the previous year[23] - The company reported an increase in investment income by 1646.10% to CNY 2,463,766.47 from CNY 141,101.23 in the previous year[23] - Research and development expenses rose to ¥61,517,923.07 from ¥56,659,055.19, reflecting an increase of about 8.73%[32] - Tax expenses decreased to ¥1,076,155.70 from ¥6,010,278.61, a reduction of approximately 82.06%[34] - The company reported a financial asset impairment loss of ¥-1,694,678.65, compared to ¥-1,250,138.89 in the previous period[34] - Other income decreased to ¥9,070,325.65 from ¥13,015,588.30, indicating a decline of about 30.38%[32]